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To investigate the relationship between the ratio of monocytes infiltrating renal cel carcinoma 
(RCC) and prognosis， in78 patients who underwent nephrectomy， the positive rate of the following 
parameters was assessed immunohistochemically under light microscopy: tumor-associated 
macrophage (TAM)， microvessel density (MVD)， S-100 cel， HLA-DR cell， apoptosis index (AI) and 
proliferative index (PI). The relationship between the positive rate ofthese parameters and prognosis， 
and intercorrelations among these parameters were analyzed. A positive correlation with prognosis 
was observed in patients positive for TAM， MVD or PI (r=0.625). Prognosis was poor for patients 
with high levels ofthese parameters. Furthermore， the number ofS・100-positivecells was a prognostic 
factor only in patients with metastatic RCC. Although the role of T AM asa prognstic factor in RCC 
is clear， no linear relationship was identified between prognosis and other monocytes. 
(Acta Urol. Jpn. 48: 213-220， 2002) 


































































associated macrophage (T AM)， micro-vessel densi-
ty in the tumor (MVD) ， S-100蛋白陽性細胞 (S-
100 (+)細胞)， HLA-DR陽性細胞 (HLA-DR(+)
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Primary antibodies used for evalua-
tion of TAM， MVD， S-100( +) cell， 
HLA-DR( +) cel and PI 
Primarv anti-human CD68/horseradish 
peroxide monoclonal antibodies (DAKO 
]APAN， Kyoto， ]apan) 
Anti-factor VIII-related antI!ren仁Dako
Corporation， Santa Barbara， CA， USA) 
Primary Rabbit anti-S-IOO antibodies 
{:Qako Corporation， Carpinteria， CA， 
USA) 
Monoclonal mouse anti-human HLA-
DR alpha-chain (DAKO， Denmark) 








AIの染色は TUNEL法 (ApopDETEKCell 
Death Assay System， Enzo Diagnostics， Inc. 
Famingdale， NY; USA)で行った8) 評価は400倍
顕微鏡下で腫蕩細胞1.000個中の染色された細胞数の
比率を AIとした.
統計学的検討は TAM. MVD， S-100(+)細胞，











Table 2. Results of TAM， MVD， S-100(+) 
cell， HLA-DR( +) cell， AI and PI， 
and pathological characteristics in 78 
patIents 
TAM(m×a4g0m0l aca-Minimal 
tlOn， Max 恥1ean Median 
~ 本 o (n= 3) 104.1 33.95 33.4 
b** o (n=15) 70 11.72 8.0 
c*申本 o (n=15) 42 6.82 4.0 
MVD jmag耐
tion， X200) 133 33.28 28 
S-IOO( +) cel (magnification， X 100) 
a 牢 o (n=15) 98 10.27 5.0 
b** o (n=28) 100 13.46 9.0 
c事事事 o (n=17) 60 6.62 3.0 
HLA-DR( +) cel (magnification， X 100) 
a* o (n=15) 337 52.72 31 
b** o (n=28) 99 11.42 3 
c本市本 o (n=17) 169 37.38 25 
A×l40(Om，移~)ification ， 0.1 12 3.21 2.4 
P×l40(0m，t9F6) niaut10n，0.I 65.4 6.71 3.9 
Grade GI; 26 G2; 45 G3; 7 
T criteria Tl/2; 42 T3/4; 36 
V criteria V(-); 47 V(+); 31 
M criteria MO; 59 乱11;19 
* The tumor center，判 Theboundary between tumor 
tissue and normal renal tissue，帥*in the connective tis-
sue around intratumoral main vessel. 
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Table 3. Correlation between classical prognostic factors and the mean values ofTAM， MVD， S-100(十)
cell， HLA・DR(+) cell， AI and PI in al the patients 
TAM MVD S-lOO( +) cel HLA-DR(+) cel AI PI 
MO (n=59) 30.9:t2.8 28.8:t 2.2 9.7:t2.0 55.8:t 8.6 2.9:t0.3 5.9:t 1.3 
M1 (n=19) 43.3土3.9 47.3:t 6.6 11.8土4.2 43.1 :士17.4 4.1:t0.7 9.0:t 1.1 
P value <0.01 <0.01 n.s n.s n.s n.s 
Grade 1 (n=26) 3 1.2:t 4.6 29.9土4.3 15目O土4.6 49.9:t 11.9 3.4:t0.5 3.7:t 1.0 
Grade 2 (n=45) 32.8:t2.6 30.8:t 2目。 7.6:t1.6 49.5:t 9.3 3.0:t0.4 8.2:t 1.6 
Grade 3 (n=7) 52.1士9.6 61.3士15.6 9.5:t3.6 83.7:t47.1 3.3:t 1.2 8.2:t2.6 
P value <0.0デ <0.05ネ n.S n.s n.s n.s 
<0.05料 <0.01料 (0.07) (0.06) 
T1/2 (n=42) 31.7土3.5 32.2:t 3.0 11.6土3.2 48.8土 9.5 2.9:t0.4 5.8:t 1.7 
T3/4 (n=36) 36.5土3.1 34.5士 4.0 8.7:t 1.5 57.3:t 12.7 3.5土0.5 7.8士1，0
P value n.s n.s n.s n.s n.s n.s 
V(-) (n=47) 32.8:t3.5 34.7:t 3.4 12.7土2.9 48.5土8.7 2.9土0.4 4.4:t 1.5 
V(+) (n=31) 35.7:t2.9 31.1:t 3.4 6.4土1.2 59.0土14.5 3.7土0.5 7.0:t1.l 
P value n.S n.S n.S n.S n.s n.s 
(0.09) 



















をTable3に示す TAM， MVDは，いずれも MO
群に比し MI群で有意な高値を示したが， T 
criteria， V criteriaでは有意差を認めなかった.また
grade 3の7例では TAM，MVDのいずれも他の2
群に比し高値を示した. S-100 (+)細胞は gradeと
V criteriaにおいて有意な相関を認めなかったが，
high-risk group (high grade， V ( + ) )で浸潤数が少




をTable4に示す TAM (p<O.OI， Fig. 1)， MVD 
(p=0.0303) ， PI (p<O.OI)はいずれも高値群が予後
Table 4. The survival rate of al the patients 
using monovariate analysis (Kaplan-
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日 lowTAMgroup (n回39)










20 40 60 80 100 120 140 (months) 
Survival curves of patients with high and low T AM 
value in al patients (n=78). Pat日ntswith a high 
TAM value showed a significantly worse survival 
than those with a low TAM value (p<O.OI). 
O 
Fig. 1. 
lowTAM group (n=20) 










20 40 60 80 100 120 140 (months) 
Survival curves of patients with high and low T AM 
values in low MVD value patients (n=39). Patients 
with a high T AM value showed a significantly worse 
survival than those with a low TAM value (p<O.Ol). 
















Table 5. Correlation between TAM and other 
factors examined (n=78) 
TAM: MVD r=0.652 <0.01 
TAM: PI r=0.42 <0.01 
TAM: S-IOO( +) cel r=ー 0.01 n.S 
TAM: HLA-DR(+) cel r=0.52 <0.01 
TAM:AI r=0.08 n.s 
MVD:PI r=0.283 <0.05 
MVD: HLA-DR( +) cel r=0.330 <0.01 
PI: HLA・DR(+)cel r=0.253 <0.05 
AI: PI r=0.316 <0.01 
相関は TAMとMVDの相関よりも低かった (r=
0.42). MVDと PIも低い相関 (r=0.283)であっ
た. HLA-DR(+)細胞は Kaplan-Meier法の結果で
は，予後に影響していないにもかかわらず TAM




















The survival rate of al patients us-
ing Cox multivariate logistic regres-








































































(TAM: l=6.660， MVD: l=8.099)， 
(l=4.624) ， MVD (l=4.278)であった.
外の各国子は予後因子として認めなかった.
high S-100 group (n=9) 






20 40 60 80 100 (months) 
Survival curves of patients with high and low S-
100(+) cell values in Ml group patients (n=19). 
Patients with a low S-lOO( +) cell value seemed to 
show worse survival than those with a S-lOO( +) cell 




high AI group (n=9) 





20 40 60 80 100 (months) 
Survival curves of patients with high and low AI 
values in Ml group patients (n=19). Patients 
with a low AI value showed a significantly worse 
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